Prosecution Insights
Last updated: November 20, 2026
Application No. 18/643,207

PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS

Final Rejection §DOUBLEPATENT
Filed
Apr 23, 2024
Priority
Feb 05, 2018 — provisional 62/626,567 +3 more
Examiner
KOSTURKO, GEORGE W
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Vertex Pharmaceuticals Incorporated
OA Round
3 (Final)
55%
Grant Probability
Moderate
4-5
OA Rounds
1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
402 granted / 736 resolved
-5.4% vs TC avg
Strong +49% interview lift
Without
With
+48.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
34 currently pending
Career history
782
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
40.5%
+0.5% vs TC avg
§102
15.4%
-24.6% vs TC avg
§112
24.4%
-15.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 736 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1, 3, 10-11, 14, 18-20, 22-23 and 28-35, filed 09/04/2026 are currently pending. Status of Claims As indicated in the Office Action of 09/08/2025, claims 10-11 and 28-29 were withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 08/04/2025. Response to Amendment Applicant’s amendments, filed 09/04/2026 are acknowledged. The phrase “about” was removed from the pending claims. Applicant's arguments, filed 09/04/2026 have been fully considered. Rejections and/or objections not reiterated from the previous Office Action are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set of rejections and objections presently being applied to the instant application. Double Patenting-Rejection Maintained The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 3, 14, 18-20, 22-23, and 30-35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 11,179,367. Although the claims at issue are not identical, they are not patentably distinct from each other because of the following. Claims 1-9 of U.S. Patent 11,179,367 are directed to a composition comprising compound (I), compound (II) and compound (III) wherein Compound (I) is present in an overlapping range of 10-100 mg, Compound (II) is present in an overlapping range of 25-70 mg and Compound (III) is present in 85-195 mg. Claims 1-9 embrace wherein Compound (II) is present in a solid dispersion comprising 80% wt. of Compound (II) and 20% wt. hydroxypropyl methylcellulose relative to the solid dispersion and wherein Compound (III) is also present in a second solid dispersion comprising 80% wt. Compound (III), 19.5% wt. hydroxypropyl methylcellulose and 0.5% wt. sodium lauryl sulfate relative to the total weight of the second solid dispersion. Claim 2 embodies overlapping 30-120 mg of compound I, overlapping 15-60 mg of compound II and overlapping 20-90 mg of compound III. Claims 1-9 embrace wherein the tablet comprises croscarmellose sodium, microcrystalline cellulose and magnesium stearate. Claims 7-9 of U.S. Patent 11,179,367 embraces wherein Compound (I) is present in crystalline Form (A). Claims 10-11 of U.S. Patent 11,179,367 are directed to the treatment of cystic fibrosis in a subject in need comprising administering a therapeutically effective amount of a composition comprising compound (I), (II) and (III) which overlaps with the subject matter embraced in present claims 10-11. The amounts of Compound (I), (II) and (III) in the pharmaceutical composition overlap with the amounts embraced within the present claims. Applicant is reminded of MPEP 2144.05 wherein in the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). Accordingly, said skilled artisan would have found it prima facie obvious to select Compound (I) in crystalline Form (A) at a dose of 100 mg and combine it with 50 mg of compound II formulated in a first solid dispersion comprising 10-30% wt. of a polymer relative to the total weight of the dispersion and 75 mg of compound III formulated in a second solid dispersion comprising 10-30% wt. of a polymer relative to the total weight of the dispersion, or alternatively select Compound (I) in crystalline Form (A) at a dose of 50 mg and combine it with 25 mg of compound II formulated in a first solid dispersion comprising 10-30% wt. of a polymer relative to the total weight of the dispersion and 37.5 mg of compound III formulated in a second solid dispersion comprising 10-30% wt. of a polymer relative to the total weight of the dispersion in view of claims 1-9 of U.S. Patent No. 11,179,367, arriving at the presently claimed compositions with a reasonable expectation of success. Applicant is reminded that “[I]t is well settled that it is a matter of obviousness for one of ordinary skill in the art to select a particular component from among many disclosed by the prior art as long as it is taught that the selection will result in the disclosed effect, even when the possible selections number 1200 or in the thousands. Merck & Co., Inc. v. Biocraft Labs., Inc., 874 F.2d 804, 807 (Fed. Cir. 1989); In re Corkill, 771 F.2d 1496, 1500 (Fed. Cir. 1985).” Applicant is also reminded of MPEP 2144.07 wherein the selection of a known material based on its suitability for its intended use supported a prima facie obviousness determination in Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945). In the instant case, claims 1-9 of U.S. Patent 11,179,367 teaches that a composition comprising any dose within the range of 15-250 mg of Compound I in crystalline form A is suitable to combine with any dose within the range of 10-150 mg of compound II formulated in a first solid dispersion comprising 10-30% wt. of a polymer relative to the total weight of the dispersion and any dose within the range 25-200 mg of compound III formulated in a second solid dispersion comprising 10-30% wt. of a polymer relative to the total weight of the dispersion in order to yield a composition that is efficacious at treating cystic fibrosis in a subject in need. As such, said skilled artisan would have readily selected a dose of 100 mg of Compound I in crystalline Form A and combined it with 50 mg of compound II formulated in a first solid dispersion comprising 10-30% wt. of a polymer relative to the total weight of the dispersion and 75 mg of compound III formulated in a second solid dispersion comprising 10-30% wt. of a polymer relative to the total weight of the dispersion; or alternatively, readily selected a dose of 50 mg of Compound I in crystalline Form A, and combined it with 25 mg of compound II formulated in a first solid dispersion comprising 10-30% wt. of a polymer relative to the total weight of the dispersion and 37.5 mg of compound III formulated in second solid dispersion comprising 10-30% wt. of a polymer relative to the total weight of the dispersion from within the amounts of compounds I, II and III embraced within claims 1-9 of U.S. Patent 11,179,367 with a reasonable expectation that the selected amounts of Compound I, Compound II and Compound III in the disclosed composition would yield an efficacious composition for treating cystic fibrosis in an afflicted subject. It is noted that claims 1-9 of U.S. Patent 11,179,367 do not explicitly teach wherein compound (I) is present in an amount of 100 mg (claim 1), or 50 mg (claim 3), wherein compound (II) is present in an amount of 50 mg (claim 1) or 25 mg (claim 3), or compound III is present in 75 mg (claim 1) or 37.5 mg (claim 3). However, it is considered well within the capabilities of one of ordinary skill in the art to optimize the amount of Compound (I)-(III) and the excipients in the pharmaceutical composition. The amount of Compounds (I)-(III) in the pharmaceutical composition as well as the amounts of pharmaceutical excipients are each result effective parameters that will affect the physical properties of the final composition. The amount of Compound (I)-(III) in the pharmaceutical composition as well as the amount of excipients HPMC-AS, microcrystalline cellulose, croscarmellose sodium and magnesium stearate in the composition are each clearly a results effective parameter that a person of ordinary skill would routinely optimize. Optimization of parameters is a routine practice that would have been obvious for a person of ordinary skill in the art to employ and reasonably would expect success. Moreover, the amounts embraced within claims 1-9 of U.S. Patent 11,179,367 provide a range of workable amounts of Compound (I)-(III) as well as a workable range for HPMC-AS, microcrystalline cellulose, croscarmellose sodium and magnesium stearate in the pharmaceutical composition and it would have been customary for an artisan of ordinary skill to determine the optimal amount of each active agent and each pharmaceutical excipient to best achieve the desired result. Furthermore, absent any evidence demonstrating a patentable difference between the composition and the criticality of the claimed amounts, the determination of the optimum workable range(s) given the guidance of the prior art would have been generally prima facie obvious to the skilled artisan. Please see MPEP 2144.05 [R-2](II) (A) and In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) “[W]here the general conditions of the claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.") Applicant traverses. Applicant argues that the ‘367 patent recites broad independent ranges for each compound and does not identify a proportional relationship among Compounds I, II and III, nor provide a reason to select and preserve the 4:2:3 ratio of Compound I, Compound II and Compound III in the pharmaceutical composition particular ratio across two dose strengths. Applicant additionally argues that the Office has not shown the claimed selections result from routine optimization of known result effective variables. Response to Arguments Applicant’s arguments, filed 09/04/2026 are acknowledged and have been carefully considered. Applicant argues that the ‘367 patent recites broad independent ranges for each compound and does not identify a proportional relationship among Compounds I, II and III, nor provide a reason to select and preserve this particular ratio across two dose strengths. This argument is unavailing. The selection of a known material based on its suitability for its intended use is an established rationale to support a prima facie obviousness determination. See MPEP 2144.07. In the present case, claim 2 of U.S. Patent 11,179,367 is directed to a composition comprising 30-120 mg Compound (I), 15-60 mg Compound (II) and 20-90 mg Compound III and said composition is suitable for the intended purpose of treating cystic fibrosis (claims 1, 2 and 10). As cited in the rejection above, doses of active pharmaceutical ingredients in pharmaceutical compositions are, in general, a result effective variable. It is within the level of ordinary skill in the art to adjust the dosage amounts in response to the therapeutic need of a patient and the clinical situation at hand. One would have therefore viewed the dosage of Compound I, II and III in the present claims as being a matter of optimization of dosing amount within the general teachings of the cited reference. It appears that Applicant has simply identified a 4:2:3 ratio of Compound I, Compound II and Compound III, a ratio that lies inside the genus of Compound I, Compound II and Compound III in the pharmaceutical composition of U.S. Patent 11,179,367 and a ratio that is reached by practicing routine procedures and producing predictable results. The instant situation is amenable to the fact pattern of Tyco Healthcare V. Mutual Pharma (Fed. Circ. 2011) which rendered specific dosages of 6-8 mg of temazepam prima facie obvious in view of the prior art disclosed dosage range of 5-15 mg. The court stated that "[ordinarily, 'where there is a range disclosed in the prior art, and the claimed invention falls within that range, there is a presumption of obviousness." See Iron Grip Barbell Co., Inc. v. USA Sports, Inc., 392 F.3d 1317, 1322, 73 USPQ2d 1225, 1228 (Fed. Cir. 2004). The Federal Circuit explained this presumption can be rebutted "by a showing that the prior art taught away from the invention or by a showing of new and unexpected results relative to the prior art." In the instant case, there is no teaching away within U.S. Patent 11,179,367 to a dose of 100 mg of Crystalline Form A of Compound I; 50 mg of Compound II and 75 mg of Compound III, nor is there a teaching away within U.S. Patent 11,179,367 to a dose of 50 mg of Crystalline Form A of Compound I; 25 mg of Compound II and 37.5 mg of Compound III from the genus of a composition comprising compound (I), compound (II) and compound (III) wherein 30-120 mg Compound (I), 15-60 mg Compound (II) and 20-90 mg Compound III provided in U.S. Patent 11,179,367. Nor were any unexpected results demonstrating criticality of these specific doses of Crystalline Form A of Compound I, Compound II and Compound III relative to the therapeutic ranges of each compound recited U.S. Patent 11,179,367. Therefore, the rejection is maintained. Conclusion In view of the rejection set forth above, no claim is allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GEORGE W KOSTURKO whose telephone number is (571)270-5903. The examiner can normally be reached M-F 9:00-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, CLINTON A BROOKS can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GEORGE W KOSTURKO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Apr 23, 2024
Application Filed
Sep 08, 2025
Non-Final Rejection mailed — §DOUBLEPATENT
Mar 06, 2026
Response Filed
May 20, 2026
Non-Final Rejection mailed — §DOUBLEPATENT
Sep 04, 2026
Response Filed
Nov 12, 2026
Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797390
INHIBITORS OF DNA PK AND USES THEREOF
2y 9m to grant Granted Nov 17, 2026
Patent 12773412
GANAXOLONE FOR USE IN TREATMENT OF SUPER REFRACTORY STATUS EPILEPTICUS
3y 5m to grant Granted Oct 27, 2026
Patent 12766120
COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT
3y 10m to grant Granted Oct 20, 2026
Patent 12766119
METHODS OF TREATING SEIZURE DISORDERS AND PRADER-WILLI SYNDROME
2y 8m to grant Granted Oct 20, 2026
Patent 12767655
Cathinone Derivatives, Pharmaceutical Formulations, and Methods
2y 8m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
55%
Grant Probability
99%
With Interview (+48.9%)
2y 8m (~1m remaining)
Median Time to Grant
High
PTA Risk
Based on 736 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month